Editorial Views  |   September 2016
Duloxetine for Subacute Pain Management after Total Knee Arthroplasty: Should We Write It Off or Reevaluate?
Author Notes
  • From the Department of Physical Medicine and Rehabilitation, Walter Reed National Military Medicine Center, Bethesda, Maryland (M.B.J.); Uniformed Services University of the Health Sciences, Bethesda, Maryland (M.B.J., S.P.C.); and Departments of Anesthesiology and Critical Care Medicine and Physical Medicine and Rehabilitation, Johns Hopkins School of Medicine, Baltimore, Maryland (S.P.C.).
  • Corresponding article on page 561.
    Corresponding article on page 561.×
  • This editorial discusses an off-label use of a U.S. Food and Drug Administration–approved medication.
    This editorial discusses an off-label use of a U.S. Food and Drug Administration–approved medication.×
  • Accepted for publication May 23, 2016.
    Accepted for publication May 23, 2016.×
  • Address correspondence to Dr. Cohen:
Article Information
Editorial / Pain Medicine / Pharmacology
Editorial Views   |   September 2016
Duloxetine for Subacute Pain Management after Total Knee Arthroplasty: Should We Write It Off or Reevaluate?
Anesthesiology 9 2016, Vol.125, 454-456. doi:
Anesthesiology 9 2016, Vol.125, 454-456. doi:

“[The authors] sought to determine whether duloxetine improves sub-acute pain after total knee arthroplasty.”

Image: Thinkstock Image.
Image: Thinkstock Image.
Image: Thinkstock Image.
ALL actions have predictable and unpredictable consequences. As a result of the confluence of the rapidly escalating costs of conducting randomized controlled trials and the decline in federal research funding, industry has munificently stepped in to fill the gap. But whereas this has led to some major breakthroughs in pain medicine, it comes at a price. Industry-sponsored studies are 3.6 to 4 times more likely to yield positive results than non–industry-sponsored studies, which is a figure that is even further skewed by publication bias.1  In contrast to large pragmatic and comparative-effectiveness studies that seek to measure benefit in real-life circumstances, the objectives of efficacy studies are intricately tied to those of the stakeholders (i.e., companies) that sponsor them and generally focus on teasing out small effect sizes in an ideal patient population (i.e., those with short duration of pain, moderate disease burden, not taking opioids, no coexisting psychosocial issues, etc.) that rarely reflects those encountered in clinical practice. Yet, even under these idyllic circumstances, the difference separating the treatment from placebo group is usually very small, averaging around 10 to 20% in studies evaluating duloxetine for knee osteoarthritis.2,3  Whereas a two-point or 30% diminution in pain has been shown to constitute a clinically meaningful reduction on an individual basis, these same Initiative on Methods, Measurement and Pain Assessment in Clinical Trials guidelines note that smaller differences between groups can be considered clinically relevant in clinical trials.4  Therefore, a non–industry-sponsored, blinded study that seeks to determine efficacy in a real-world population is greatly needed, and the authors should be applauded for undertaking this endeavor.
In this issue of Anesthesiology, in a triple-blinded, placebo-controlled study, YaDeau et al.5  sought to determine whether duloxetine improves subacute pain after total knee arthroplasty (TKA). Duloxetine is approved by the U.S. Food and Drug Administration for the treatment of chronic musculoskeletal pain, including osteoarthritis and low back pain, and has been shown in controlled trials to reduce pain and opioid consumption in a perioperative setting,6,7  including a study that examined the effect of two doses given before and after knee replacement.6  Hence, the hypothesis proposed by YaDeau et al.5  was a sound one.
Arthritis is one of the three leading causes of disability,8  so it is not surprising that the rate of TKA is rapidly rising in our aging population. There are over 700,000 TKA procedures performed annually, making it the most common surgical procedure associated with a hospital stay.9  Between 1991 and 2010, the volume of primary TKA in the United States increased over 160%.10  Importantly, TKA is cost-effective and improves functional status and quality of life.11 
Answering the question proposed by YaDeau et al.5  carries the potential for far greater implications than merely reducing postoperative pain and opioid use because there is a growing body of literature suggesting that rehabilitation may improve arthroplasty outcomes and that pain control without limiting adverse effects, such as sedation, can improve rehabilitation.12  To test their hypothesis, 106 patients were randomized to receive either duloxetine or placebo for 15 days, starting on the date of surgery. Patients in both groups also received a comprehensive multimodal analgesic regimen, which included neuraxial anesthesia, epidural analgesia, adductor canal block, meloxicam, and oxycodone/acetaminophen as needed. Although patients on duloxetine did reduce their opioid use, the primary outcome of pain with ambulation, as well as pain at rest, did not differ significantly from placebo 2 weeks postoperatively.
One of the many strengths of this study is that it was triple blinded, and the investigators evaluated a proven drug in a clinically meaningful context for a condition in which there is little available information. Whereas the number of knee arthroplasties has increased substantially, this increase has not been accompanied by a commensurate increase in the analgesic options that can facilitate earlier and longer ambulation. Choosing a functionally relevant outcome measure was both patient centered and insightful, as the 2-week postoperative period is a critical window during which rehabilitation may improve long-term results. For mechanical conditions such as joint pain, reducing pain during ambulation is more important than reducing pain at rest, although the latter is by far a more common primary outcome measure in clinical trials. Yet, choosing a primary outcome measure assessed at a cross-section in time may be less accurate than averaging multiple pain recordings (e.g., by using an electronic device) and less relevant than measuring the trajectory of recovery or improvement. Despite the many strong points, several important limitations in study design may have yielded inauspicious results. It is likely that this study was underpowered, as pain scores in the duloxetine group were approximately 10% lower than those in the placebo group, and a 10% difference between treatment and control groups is not unusual for U.S. Food and Drug Administration–approved adjuvant pain medications.13  As referenced earlier, this may have been due to reliance on industry-sponsored studies, where the patients are more stringently selected and the magnitude of effect is typically greater. This can result in failure to recruit enough patients (type II error), which can lead to the inappropriate dismissal of a potentially beneficial intervention with a favorable side-effect profile. In addition, many experts have argued that because the availability of “rescue” medications is an essential element in all perioperative pain trials, opioid use, rather than pain scores, should be the primary outcome measure.14  Regardless of treatment allocation, all patients in this study received an effective, multimodal pain treatment regimen, which often translates into decreased postoperative pain. Well-controlled postoperative pain is less likely to become chronic postsurgical pain. As was pointed out in a previous Anesthesiology editorial on the ability of epidural analgesia to prevent phantom limb pain,15  studies in which the control group receives very good perioperative analgesia are more likely to yield negative findings than those in which the control group receives suboptimal pain management.
The choice of dose provided to study patients (i.e., 60 mg duloxetine daily) also deserves scrutiny. As the basis for this decision, the authors cited studies showing that 120 mg was not more effective than 60 mg for neuropathic pain.16  However, postarthroplasty pain is generally inflammatory in nature, and even in chronic postsurgical pain after knee arthroplasty, only 6% of cases are predominantly neuropathic.17  Previous randomized studies evaluating duloxetine for knee osteoarthritis used a dose range of 60 to 120 mg, suggesting that at least in some patients, the dosage studied may have been too low.2,3,18 
In conclusion, we believe that while the study by YaDeau et al.5  was generally well designed, pragmatic, and sought to answer an important question, the results should not be construed as definitive; instead, they should be used to inform more research into this area. As our population ages and opioid abuse continues to ravage communities, finding pain-reducing and opioid-sparing treatments for postarthroplasty pain is a worthwhile endeavor that we must continue to pursue.
Research Support
Supported by the Centers for Rehabilitation Sciences Research, Bethesda, Maryland (to Dr. Cohen). The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of Navy or the Department of Defense.
Competing Interests
The authors are not supported by, nor maintain any financial interest in, any commercial activity that may be associated with the topic of this article.
Bekelman, JE, Li, Y, Gross, CP Scope and impact of financial conflicts of interest in biomedical research: A systematic review.. JAMA. (2003). 289 454–65 [Article] [PubMed]
Chappell, AS, Desaiah, D, Liu-Seifert, H, Zhang, S, Skljarevski, V, Belenkov, Y, Brown, JP A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee.. Pain Pract. (2011). 11 33–41 [Article] [PubMed]
Chappell, AS, Ossanna, MJ, Liu-Seifert, H, Iyengar, S, Skljarevski, V, Li, LC, Bennett, RM, Collins, H Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial.. Pain. (2009). 146 253–60 [Article] [PubMed]
Dworkin, RH, Turk, DC, Wyrwich, KW, Beaton, D, Cleeland, CS, Farrar, JT, Haythornthwaite, JA, Jensen, MP, Kerns, RD, Ader, DN, Brandenburg, N, Burke, LB, Cella, D, Chandler, J, Cowan, P, Dimitrova, R, Dionne, R, Hertz, S, Jadad, AR, Katz, NP, Kehlet, H, Kramer, LD, Manning, DC, McCormick, C, McDermott, MP, McQuay, HJ, Patel, S, Porter, L, Quessy, S, Rappaport, BA, Rauschkolb, C, Revicki, DA, Rothman, M, Schmader, KE, Stacey, BR, Stauffer, JW, von Stein, T, White, RE, Witter, J, Zavisic, S Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.. J Pain. (2008). 9 105–21 [Article] [PubMed]
YaDeau, JT, Brummett, CM, Mayman, DJ, Lin, Y, Goytizolo, EA, Padgett, DE, Alexiades, MM, Kahn, RL, Jules-Elysee, KM, Fields, KG, Goon, AK, Gadulov, Y, Westrich, G Duloxetine and subacute pain after knee arthroplasty when added to a multimodal analgesic regimen: A randomized, placebo-controlled, triple-blinded trial.. Anesthesiology. (2016). 125 561–72
Ho, KY, Tay, W, Yeo, MC, Liu, H, Yeo, SJ, Chia, SL, Lo, NN Duloxetine reduces morphine requirements after knee replacement surgery.. Br J Anaesth. (2010). 105 371–6 [Article] [PubMed]
Hyer, L, Scott, C, Mullen, CM, McKenzie, LC, Robinson, JS Randomized double-blind placebo trial of duloxetine in perioperative spine patients.. J Opioid Manag. (2015). 11 147–55 [Article] [PubMed]
Messier, SP, Mihalko, SL, Legault, C, Miller, GD, Nicklas, BJ, DeVita, P, Beavers, DP, Hunter, DJ, Lyles, MF, Eckstein, F, Williamson, JD, Carr, JJ, Guermazi, A, Loeser, RF Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: The IDEA randomized clinical trial.. JAMA. (2013). 310 1263–73 [Article] [PubMed]
Most Frequent Operating Room Procedures Performed in U.S. Hospitals, 2003–2012, (2014). Available at: Accessed May 9, 2016
Cram, P, Lu, X, Kates, SL, Singh, JA, Li, Y, Wolf, BR Total knee arthroplasty volume, utilization, and outcomes among Medicare beneficiaries, 1991–2010.. JAMA. (2012). 308 1227–36 [Article] [PubMed]
Losina, E, Walensky, RP, Kessler, CL, Emrani, PS, Reichmann, WM, Wright, EA, Holt, HL, Solomon, DH, Yelin, E, Paltiel, AD, Katz, JNCost-effectiveness of total knee arthroplasty in the United States: Patient risk and hospital volume.. Arch Intern Med. (2009). 169 1113–21discussion 1121–2 [Article] [PubMed]
Westby, MD Rehabilitation and total joint arthroplasty.. Clin Geriatr Med. (2012). 28 489–508 [Article] [PubMed]
Mou, J, Paillard, F, Turnbull, B, Trudeau, J, Stoker, M, Katz, NP Efficacy of Qutenza® (capsaicin) 8% patch for neuropathic pain: A meta-analysis of the Qutenza Clinical Trials Database.. Pain. (2013). 154 1632–9 [Article] [PubMed]
Berde, CB, Walco, GA, Krane, EJ, Anand, KJ, Aranda, JV, Craig, KD, Dampier, CD, Finkel, JC, Grabois, M, Johnston, C, Lantos, J, Lebel, A, Maxwell, LG, McGrath, P, Oberlander, TF, Schanberg, LE, Stevens, B, Taddio, A, von Baeyer, CL, Yaster, M, Zempsky, WT Pediatric analgesic clinical trial designs, measures, and extrapolation: Report of an FDA scientific workshop.. Pediatrics. (2012). 129 354–64 [Article] [PubMed]
Rathmell, JP, Kehlet, H Do we have the tools to prevent phantom limb pain?. Anesthesiology. (2011). 114 1021–4 [Article] [PubMed]
Lunn, MP, Hughes, RA, Wiffen, PJ Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia.. Cochrane Database Syst Rev. (2014). 1 CD007115 [PubMed]
Haroutiunian, S, Nikolajsen, L, Finnerup, NB, Jensen, TS The neuropathic component in persistent postsurgical pain: A systematic literature review.. Pain. (2013). 154 95–102 [Article] [PubMed]
Frakes, EP, Risser, RC, Ball, TD, Hochberg, MC, Wohlreich, MM Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: Results of a randomized, double-blind, placebo-controlled trial.. Curr Med Res Opin. (2011). 27 2361–72 [Article] [PubMed]
Image: Thinkstock Image.
Image: Thinkstock Image.
Image: Thinkstock Image.